STCube

STCube Intangible Assets

The Intangible Assets of STCube (052020.KQ) as of Oct 24, 2026 is 392.82 M KRW. In the previous year, Intangible Assets was 367.92 M KRW — a change of 6.77% (higher).

Intangible Assets

392.82 MKRW

YoY

6.77%

Last updated:

Intangible Assets of STCube is 2024 392.82 M KRW. Intangible Assets of STCube was 2023 367.92 M KRW. It decreases by 6.77% higher compared to the previous year.

The STCube Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
7.59 B KRW
Jan 1, 2018
7.01 B KRW
Jan 1, 2019
93.00 M KRW
Jan 1, 2020
67.05 M KRW
Jan 1, 2021
386.78 M KRW
Jan 1, 2022
370.48 M KRW
Jan 1, 2023
367.92 M KRW
Jan 1, 2024
392.82 M KRW
The STCube Intangible Assets history
YEARIntangible AssetsYoY
392.82 MKRW+6.77%
367.92 MKRW-0.69%
370.48 MKRW-4.21%
386.78 MKRW+476.85%
67.05 MKRW-27.90%
93.00 MKRW-98.67%
7.01 BKRW-7.59%
7.59 BKRW-10.30%
8.46 BKRW+106.14%
4.10 BKRW+218.39%
1.29 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Intangible Assets of STCube is 392.82 M KRW in 2024.

Intangible Assets of STCube changed from 367.92 M KRW to 392.82 M KRW, representing a 6.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets STCube since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's STCube historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — STCube

All Key Metrics — STCube